Medication info
Pregabalin Capsules 25 mg

Pregabalin Capsules 25 mg

Prescription medicationHard capsule
Ingredient · strength
Pregabalin›25mg / 1 capsule
Manufacturer / importer
Genupharm Co., Ltd.
Appearance
A hard capsule with a light yellow upper part and a white lower part containing white powder.
Packaging
30 capsules/bottle
Approval status
Active

MFDS item code 201906161 · Approved 2019.08.29 · Insurance code 698004150

Summary

Main use
Treatment of neuropathic pain and fibromyalgia, adjunctive treatment of partial-onset epileptic seizures
Who uses it
Adults · Children
Adult dosage
This medicine is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine (mg/dL) * For women, multiply the result obtained using the above formula by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1] Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalina Dosage regimen Initial dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30-<60 75 300 BID or TID ≥15-<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Administered once daily a: The total daily dose (mg/day) should be divided as specified in the dosage regimen. b: Supplemental dose refers to a dose administered as a single additional dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children's dosage
Children under 12 years of age: As there are insufficient safety and efficacy data, use is not recommended. Adolescent patients aged 12-17 years: As there are insufficient safety and efficacy data, use is not recommended.

Ingredients

Manufacturer
Genupharm Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia, adjunctive treatment of partial-onset epileptic seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults. It is also used as an adjunctive treatment for partial seizures in patients with epilepsy, regardless of the presence of secondary generalized symptoms. Additionally, it is effective in the treatment of fibromyalgia. In other words, it helps alleviate pain, control seizures, and improve muscle pain.

Dosage and Administration

Adult dosage

This medicine is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine (mg/dL) * For women, multiply the result obtained using the above formula by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1] Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalina Dosage regimen Initial dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30-<60 75 300 BID or TID ≥15-<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Administered once daily a: The total daily dose (mg/day) should be divided as specified in the dosage regimen. b: Supplemental dose refers to a dose administered as a single additional dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.

Children's dosage

Children under 12 years of age: As there are insufficient safety and efficacy data, use is not recommended. Adolescent patients aged 12-17 years: As there are insufficient safety and efficacy data, use is not recommended.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors; thus, any changes in mood or symptoms of depression during administration should be reported to a healthcare professional immediately. Do not use this medication if you are allergic to it or have certain genetic conditions such as lactose intolerance. Diabetes patients may need to adjust their blood sugar medication dosage as weight gain after taking this medication can affect blood sugar control. If symptoms of angioedema, such as swelling of the face or neck, occur during treatment, discontinue use immediately and consult a healthcare professional. Elderly patients should be cautious as dizziness or drowsiness may increase the risk of falls or accidents. Transient visual disturbances or changes in vision may occur and these symptoms may improve after discontinuation of the medication. Sudden cessation of this medication may lead to withdrawal symptoms including insomnia, headaches, nausea, and anxiety; therefore, it should be reduced gradually in consultation with a healthcare provider. Caution is required when taking this medication with others that affect the central nervous system due to an increased risk of drug abuse or dependency. Dosing adjustments may be necessary for patients with impaired renal function. Patients with heart diseases or congestive heart failure should be closely monitored while using this medication. Caution is also necessary when taking this medication with opioid analgesics as it can increase central nervous system depressant effects, resulting in a risk of respiratory depression. During early pregnancy, this medication may affect the fetus; it should be avoided during pregnancy, and effective contraception should be used by women of childbearing age. During breastfeeding, this medication may be transmitted through breast milk, and should be discussed with a healthcare professional to consider stopping the drug or breastfeeding. It is advisable to avoid dangerous activities such as driving or operating machinery until dizziness or drowsiness has subsided after taking this medication. If severe rashes or blisters appear on the skin during treatment, discontinue use immediately and inform a healthcare professional. In case of overdose, symptoms such as confusion, drowsiness, and depression may occur, necessitating immediate medical attention.

Side effects

  • Suicidal ideation
  • suicidal behavior
  • depression
  • angioedema
  • facial swelling
  • perioral edema
  • upper airway edema
  • dizziness
  • drowsiness
  • loss of consciousness
Show 185 more
  • confusion
  • mental disorders
  • blurred vision
  • vision changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • thoughts of suicide
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • decreased respiratory function
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • decreased oral sensation
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • breast discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait disturbances
  • falls
  • feeling drunk
  • abnormal sensations
  • fatigue
  • feeling of tightness in the chest
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood glucose
  • decreased platelet count
  • decreased potassium in the blood
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • nasopharyngitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • hyperirritability
  • euphoria
  • decreased libido
  • depersonalization
  • sexual hyperesthesia
  • anxiety
  • mood swings
  • emotional lability
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • inability to inhibit
  • apathy
  • ataxia
  • motor coordination disturbances
  • balance disorders
  • amnesia
  • attention deficit
  • memory impairment
  • tremors
  • dysarthria
  • sensory disturbances
  • decreased sensation
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorders
  • hepatic myoclonus
  • decreased reflexes
  • movement abnormalities
  • psychomotor agitation
  • orthostatic dizziness
  • sensory hyperreactivity
  • burning sensation
  • action tremor
  • syncope
  • confusion
  • motor retardation
  • olfactory disturbances
  • loss of taste
  • writing disturbance
  • diplopia
  • auditory hypersensitivity
  • first-degree atrioventricular block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • coughing
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • headache
  • keratitis
  • pulmonary edema
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • confused state
  • agitation
  • restlessness
  • worsening of seizures
  • fatigue
  • weakness
  • gait abnormalities
  • sleep disorders
  • constipation
  • gastrointestinal disorders
  • bloody stools
  • increased BUN
  • urination difficulties
  • tinnitus
  • skin disorders

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture; therefore, it should be stored in a tightly closed container. It is best kept at room temperature between 15 to 30 degrees Celsius. This will help maintain the effectiveness of the medication for a longer period.

Appearance and packaging

Appearance

A hard capsule with a light yellow upper part and a white lower part containing white powder.

Package unit

30 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.